Skip to Main Content
Table 1.

Comparative efficacy of TKI in BA/F3 KIT double mutants, harboring either a KIT exon 9 or exon 11 primary mutation

IC50 (nmol/L)
MutationsNilotinibDasatinibSorafenib
KIT                  502-503AY/V654A 1,045 334.5 1,672 
KIT                  V560del/V654A 192 585 1,074 
KIT                  502-503AY/D820Y 248 40.6 842 
KIT                  V559D/D820Y 297 432 944 
KIT                  502-503AY/N822K 369 66.2 933 
KIT                  V560del/N822K NA NA NA 
IC50 (nmol/L)
MutationsNilotinibDasatinibSorafenib
KIT                  502-503AY/V654A 1,045 334.5 1,672 
KIT                  V560del/V654A 192 585 1,074 
KIT                  502-503AY/D820Y 248 40.6 842 
KIT                  V559D/D820Y 297 432 944 
KIT                  502-503AY/N822K 369 66.2 933 
KIT                  V560del/N822K NA NA NA 
Close Modal

or Create an Account

Close Modal
Close Modal